Genenta Science Provides Update on CEO Ownership
Rhea-AI Summary
Genenta Science (Nasdaq: GNTA) updated ownership details for CEO and co-founder Pierluigi Paracchi as of December 19, 2025. The company reports Mr. Paracchi has acquired 30,000 ADSs over time via open-market purchases and has not reported any sales in SEC filings. In total, he owns 2,326,129 ADSs and ordinary shares, representing approximately 10% of Genenta’s outstanding share capital as calculated under SEC rules.
The disclosure indicates founder insider accumulation and a sizable single-holder stake that investors may consider when evaluating free float and insider alignment.
Positive
- Insider stake of 2,326,129 shares (~10% outstanding)
- Open-market purchases of 30,000 ADSs by the CEO
- No reported sales in SEC filings by the CEO
Negative
- 10% single-holder stake may materially reduce public float
News Market Reaction 3 Alerts
On the day this news was published, GNTA declined 2.03%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.1% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $655K from the company's valuation, bringing the market cap to $32M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GNTA gained 6.47% while key biotech peers were mixed, with several (ATNM, INMB, PDSB) down between 2–4% and only VTVT modestly higher, suggesting a stock-specific move tied to the CEO ownership update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 24 | Clinical update | Positive | +6.0% | Updated TEM-GBM survival data and immune findings with stable positive trends. |
| Oct 26 | Equity offering | Negative | -46.5% | Pricing of $15M registered direct ADS offering at $3.50 per ADS. |
| Oct 24 | Strategic partnership | Positive | +92.0% | Expanded collaboration on off-the-shelf LVV plasmid DNA platform with Anemocyte. |
| Jul 01 | Clinical update | Positive | +25.4% | Long-term TEM-GBM follow-up showing favorable survival versus historical benchmarks. |
GNTA has shown strong positive reactions to clinical and partnership updates and a sharp negative move on equity financing, indicating news-type-sensitive trading behavior.
Over the last six months, GNTA reported multiple Temferon survival updates in glioblastoma, including 17‑month median overall survival and improved 18‑month and 2‑year survival signals, alongside cash of about $30 million as of Nov 1, 2025. A $15.0 million registered direct ADS offering in late October preceded a large single-day decline, while an LVV plasmid DNA partnership with Anemocyte coincided with a near-doubling of the stock. Against this backdrop, the CEO’s ~10% ownership update adds an insider-alignment data point rather than changing the clinical or financing narrative.
Market Pulse Summary
This announcement highlights that Genenta’s CEO has accumulated 30,000 ADSs via open-market purchases and, under SEC calculations, holds 2,326,129 ADSs and ordinary shares, about 10% of the company. In the context of recent GBM survival updates, a strategic LVV plasmid DNA partnership, and a $15.0 million registered direct offering, the disclosure reinforces management’s ownership alignment. Investors may watch future clinical data, additional financing steps, and any further insider ownership changes as key signals.
Key Terms
open-market purchases financial
AI-generated analysis. Not financial advice.
MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update regarding the ownership position of its Chief Executive Officer and Co-Founder, Pierluigi Paracchi.
Over time, Mr. Paracchi has acquired 30,000 American Depositary Shares (“ADSs”) of the Company in total through open-market purchases. As reported in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), Mr. Paracchi’s transactions in the Company’s securities have consisted of open-market purchases, with no reported sales.
As calculated in accordance with SEC rules, as of December 19, 2025, Mr. Paracchi owns 2,326,129 ADSs and ordinary shares in the aggregate, representing approximately
About Genenta Science
Genenta Science (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta’s first in class product candidate is Temferon™, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow-derived myeloid cells and enable a durable and targeted response. Genenta has completed the Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibition of myeloid-induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include a combination with immune checkpoint inhibitors. Genenta’s treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.
Forward-Looking Statements
Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the funding provided by the recently acquired Mandatory Convertible Bond, the Phase 1/2a clinical trial for newly diagnosed GBM patients with uMGMT-GBM, its clinical trial for metastatic RCC or any related studies, as well as Genenta’s ability to fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in Genenta's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law. This press release discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product candidates are being studied. Temferon™ is an investigational product candidate for which the effectiveness and safety have not been established. In addition, Temferon™ is not approved for use in any jurisdiction.
Genenta Science Media
Tiziana Pollio, Mobile: +39 348 23 15 143
tiziana.pollio@genenta.com
FAQ
How many shares does Genenta CEO Pierluigi Paracchi own as of December 19, 2025 (GNTA)?
How many ADSs did Pierluigi Paracchi acquire through open-market purchases for GNTA?
Has Genenta CEO Pierluigi Paracchi sold any GNTA shares according to the December 19, 2025 update?
What percentage of Genenta (GNTA) does the CEO's holding represent and how was it calculated?
Does the December 19, 2025 disclosure for GNTA indicate any planned insider selling by the CEO?
